PEOPLE YOU PROSPER WITH

Retail Equity Research Dr. Reddy's Laboratories Limited

www.geojit.com

BUY

Pharmaceuticals

BSE CODE: 500124 Bloomberg CODE: DRRD:IN NSE CODE: DRREDDY SENSEX: 60,546

KEY CHANGES:

Resilient performance; Outlook promising

Dr. Reddy's Laboratories is an Indian pharmaceutical manufacturer. The company is engaged in manufacturing and marketing of 190+ medications, 60+ APIs, as well as diagnostic kits and other biotechnology products.

TARGET

- Q2FY22 revenue rose 17.8% YoY to Rs. 5,787cr, driven by higher revenue from Global Generics (+19.0% YoY to Rs. 4,747cr).
- As a result, EBITDA grew 10.2% YoY, although EBITDA margin contracted 160bps YoY to 23.5% due to weaker mix and higher SG&A expenses (+22.0% YoY to Rs. 1,600cr). PAT rose 29% YoY to Rs. 996cr.
- Company is expected to fare well on the back drop of continued growth in revenue along with innovation of new drugs and medications. Hence, we reiterate our BUY rating on the stock with a revised target price of Rs. 5,437 using a target multiple of 23x FY23E adj. EPS.

Topline aided by new Medications

Q2FY22 revenue grew 17.8% YoY to Rs. 5,787cr, driven by significant growth in Global Generics segment (+19.0% YoY to Rs. 4,747cr) and robust performance from Proprietary Products segment (Rs. 123cr vs Rs. 10cr in Q2FY21, on the account of recognition of new license fee). This was partly offset by weaker Pharma Services and Active Ingredients segment (-1.6% YoY to Rs. 1,019cr, due to lower volumes and decrease in sales price). Resultantly, EBITDA grew 10.2% YoY to Rs. 1,360cr, although EBITDA margin contracted 160bps YoY to 23.5% dragged down by low margin product mix and higher costs. PAT registered a healthy growth of 29.0% YoY to Rs. 996cr, further helped by higher other income (Rs. 206cr vs. Rs. 27cr loss in Q2FY21).

Key Financial highlights

- Shareholding of mutual funds and institutional investors increased by 34.9% QoQ to 21.7%, offset by other shareholders that reduced to 3.6% from 8.3% previous quarter.
- Revenues from Emerging Markets at Rs. 1,300cr (+50% YoY and +42% QoQ) particularly from Russia, Romania, CIS countries.
- Dr. Reddy launched two new products this quarter i.e., Melotryp and Baricax meeting the emerging needs of the market.

COVID-19 Updates

Dr. Reddy has commercialized all its COVID-19 products launched until now, including Sputnik V vaccine, Remdesivir, Avigan (Favipiravir) and 2-deoxy-D-glucose (2-DG) in India as well as overseas. Currently, the company is conducting clinical trials for Sputnik Light, Molnupiravir and is also developing several other COVID drugs for treatment ranging from mild to severe conditions.

Valuation

Dr. Reddy is expected to fare much better backed by continued growth in revenue from COVID portfolio, contribution from new product launches and increase in sales price from current products. We expect the earnings to grow at healthy 23% CAGR over FY21-23E. Hence, we reiterate our BUY rating on the stock with a revised target price of Rs. 5,437 using a target multiple of 23x FY22E adj. EPS.


12 Months Invest	ment period	Rating as per Large Cap				
CMP Rs. 4,789 (Closing: 08-11-2		,437	RETURN 14%			

RATING 📛


EARNINGS -	
LAKIVINGS -	
	~ 2

Company Data						
Market Cap (cr)			Rs. 79,303			
Enterprise Value (cr))		Rs. 80,699			
Outstanding Shares (cr)		16.6			
Free Float			73.0%			
Dividend Yield			0.5%			
52 week high			Rs. 5,614			
52 week low			Rs. 4,136			
6m average volume (lacs)		0.5			
Beta			0.3			
Face value			Rs. 5			
Shareholding %	Q4FY21	Q1FY22	Q2FY22			
Promoters	26.7	26.7	26.7			
FII's	29.0	29.0	27.8			
MFs/Insti	15.2	16.1	21.7			
Public	20.5	19.9	20.2			
Others	8.5	8.3	3.6			
Total	100.0	100.0	100.0			
Promoters' pledge	0.0	0.0	0.0			
Price Performance	3 Month	6 Month	1 Year			
Absolute Return	1.0%	-8.0%	-2.2%			
Absolute Sensex	11.1%	22.7%	48.5%			
Relative Return*	-10.0%	-30.7%	-50.7%			

*over or under performance to benchmark index



Consolidated (cr)	FY21A	FY22E	FY23E
Sales	19,048	21,844	24,664
Growth (%)	8.7	14.7	12.9
EBITDA	4,547	5,040	6,297
EBITDA Margin (%)	23.9	23.1	25.5
Adj. PAT	2,628	2,984	3,932
Growth (%)	(29.0)	13.5	31.8
Adj. EPS	158.0	179.4	236.4
Growth (%)	(29.1)	13.5	31.8
P/E	28.6	26.6	20.2
P/B	4.3	3.9	3.4
EV/EBITDA	16.8	16.0	12.7
ROE (%)	11.1	14.8	16.7
D/E	0.2	0.1	0.1





Quarterly Financials (Consolidated)

Profit & Loss Account

	Q2FY22	Q2FY21	% YoY Growth	Q1FY22	% QoQ Growth	H1FY22	H1FY21	% YoY Growth
Revenue	5,787	4,911	17.8	4,945	17.0	10,732	9,337	14.9
EBITDA	1,360	1,234	10.2	918	48.1	2,278	2,356	(3.3)
EBITDA margins	23.5	25.1	(160bps)	18.6	490bps	21.2	25.2	(400bps)
Depreciation	294	317	(7.1)	284	3.6	578	609	(5.1)
EBIT	1,066	918	16.1	634	68.0	1,700	1,747	(2.7)
Interest	23	25	(7.1)	19	21.2	43	49	(12.0)
Other Income	206	(27)	863.9	(76)	370.8	130	60	115.3
Exceptional Items	-	-	-	-	-	-	-	-
PBT	1,248	866	44.2	539	131.4	1,787	1,758	1.6
Tax	277	101	173.7	175	57.8	452	407	11.1
Sh. of profit from Associate	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-
Reported PAT	996	772	29.0	380	161.8	1,376	1,366	0.7
Adjustments	-	-	-	-	-	-	-	-
Adj. PAT	996	772	29.0	380	161.8	1,376	1,366	0.7
No. of shares	16.6	16.6	(0.0)	16.6	0.1	16.6	16.6	(0.0)
Adj. EPS (Rs.)	59.9	46.4	29.1	22.9	161.6	82.8	82.1	0.7

Business performance

	Q2FY22	Q2FY21	% YoY Growth	Q1FY22	% QoQ Growth	H1FY22	H1FY21	% YoY Growth
Global Generics	4,747	3,988	19.0	4,125	15.1	8,872	7,497	18.3
Pharmaceutical Services and Active Ingredients	1,019	1,036	(1.6)	898	13.4	1,917	2,052	(6.6)
Proprietary Products	123	10	1,132.0	6	1,988.1	129	16	727.6
Others	60	52	14.0	48	23.4	108	101	6.6
Intersegment revenue	(162)	(175)	n.m.	(132)	n.m.	(294)	(329)	n.m.
Total revenue	5,787	4,911	17.8	4,945	17.0	10,732	9,337	14.9

Change in Estimates

	Old es	timates	New es	timates	Cha	nge %
Year / Rs. cr	FY22E	FY23E	FY22E	FY23E	FY22E	FY23E
Revenue	23,771	24,974	21,844	24,664	(8.1)	(1.2)
EBITDA	5,485	6,376	5,040	6,297	(8.1)	(1.2)
Margins (%)	23.1	25.5	23.1	25.5	0bps	0bps
Adj. PAT	3,337	3,972	2,984	3,932	(10.6)	(1.0)
Adj. EPS	200.6	238.8	179.4	236.4	(10.6)	(1.0)



PROFIT & LOSS

Y.E March (Rs. cr)	FY19A	FY20A	FY21A	FY22E	FY23E
Revenue	15,448	17,517	19,048	21,844	24,664
% change	8.2	13.4	8.7	14.7	12.9
EBITDA	3,190	4,147	4,547	5,040	6,297
% change	38.7	32.4	10.4	12.5	27.6
Depreciation	1,135	1,163	1,229	1,336	1,360
EBIT	2,055	2,984	3,318	3,704	4,937
Interest	89	98	97	73	55
Other Income	326	(1,056)	(385)	437	493
PBT	2,292	1,830	2,836	4,068	5,375
% change	69.7	(20.2)	55.0	43.5	32.1
Тах	386	(140)	932	1,139	1,505
Tax Rate (%)	16.8	(7.7)	32.9	28.0	28.0
Reported PAT	1,950	2,026	1,952	2,984	3,932
Adj*	12	1,677	677	-	-
Adj PAT	1,962	3,703	2,628	2,984	3,932
% change	107.2	88.8	(29.0)	13.5	31.8
No. of shares (cr)	16.6	16.6	16.6	16.6	16.6
Adj EPS (Rs.)	118.0	222.9	158.0	179.4	236.4
% change	107.2	88.9	(29.1)	13.5	31.8
DPS (Rs.)	20.0	25.0	25.0	30.0	35.0
CEPS (Rs.)	186.3	293.0	231.9	259.7	318.2

BALANCE SHEET

Y.E March (Rs. cr)	FY19A	FY20A	FY21A	FY22E	FY23E
Cash	223	205	1,483	1,488	1,876
Accounts Receivable	3,987	5,028	4,964	6,130	7,291
Inventories	3,358	3,507	4,541	5,481	6,252
Other Cur. Assets	3,543	3,859	3,562	3,832	4,160
Investments	334	309	833	1,988	3,150
Gross Fixed Assets	10,125	10,698	11,945	12,570	13,310
Net Fixed Assets	4,913	4,778	4,732	4,052	3,432
CWIP	473	436	954	954	954
Intangible Assets	4,739	3,171	4,085	4,054	4,054
Def. Tax (Net)	432	1,220	1,069	1,122	1,178
Other Assets	465	712	394	416	441
Total Assets	22,466	23,225	26,617	29,517	32,789
Current Liabilities	4,685	5,561	5,789	6,258	6,661
Provisions	79	75	51	61	73
Debt Funds	3,423	1,784	2,944	2,875	2,375
Other Liabilities	255	207	191	196	203
Equity Capital	83	83	83	83	83
Reserves & Surplus	13,941	15,516	17,559	20,044	23,394
Shareholder's Fund	14,024	15,599	17,642	20,127	23,477
Minority Interest	-	-	-	-	-
Total Liabilities	22,466	23,225	26,617	29,517	32,789
BVPS (Rs.)	844	939	1,061	1,210	1,412

CASH FLOW

Y.E March (Rs. cr)	FY19A	FY20A	FY21A	FY22E	FY23E
Net inc. + Depn.	3,085	3,189	3,180	4,320	5,292
Non-cash adj.	416	1,031	884	(90)	(158)
Changes in W.C	(630)	(1,236)	(494)	(1,859)	(1,768)
C.F. Operation	2,870	2,984	3,570	2,371	3,366
Capital exp.	(623)	(573)	(1,248)	(625)	(740)
Change in inv.	(228)	(21)	411	(1,100)	(1,100)
Other invest.CF	78	102	(1,429)	(0)	0
C.F – Investment	(773)	(492)	(2,266)	(1,725)	(1,840)
Issue of equity	(54)	(47)	(92)	-	-
Issue/repay debt	(1,518)	(1,868)	609	(70)	(500)
Dividends paid	(400)	(392)	(415)	(499)	(582)
Other finance.CF	(161)	(209)	(132)	(73)	(55)
C.F – Finance	(2,133)	(2,516)	(30)	(642)	(1,138)
Chg. in cash	(35)	(24)	1,275	5	389
Closing cash	223	205	1,483	1,488	1,876

RATIOS

Y.E March	FY19A	FY20A	FY21A	FY22E	FY23E
Profitab. & Return					
EBITDA margin (%)	20.6	23.7	23.9	23.1	25.5
EBIT margin (%)	13.3	17.0	17.4	17.0	20.0
Net profit mgn.(%)	12.6	11.6	10.2	13.7	15.9
ROE (%)	13.9	13.0	11.1	14.8	16.7
ROCE (%)	11.8	17.2	16.1	16.1	19.1
W.C & Liquidity					
Receivables (days)	94.2	104.8	95.1	102.4	107.9
Inventory (days)	272.7	230.4	272.7	280.0	285.4
Payables (days)	111.0	100.2	108.7	105.1	101.4
Current ratio (x)	1.9	1.7	1.8	2.0	2.2
Quick ratio (x)	1.1	1.1	1.0	1.1	1.2
Turnover & Leverage					
Gross asset T.O (x)	1.4	1.7	1.7	1.8	1.9
Total asset T.O (x)	0.7	0.8	0.8	0.8	0.8
Int. coverage ratio (x)	23.1	30.4	34.2	50.7	89.0
Adj. debt/equity (x)	0.2	0.1	0.2	0.1	0.1
Valuation					
EV/Sales (x)	3.1	3.0	4.0	3.7	3.2
EV/EBITDA (x)	15.1	12.9	16.8	16.0	12.7
P/E (x)	22.8	14.0	28.6	26.6	20.2
P/BV (x)	3.2	3.3	4.3	3.9	3.4





Dates	Rating	Target
12-Nov-19	HOLD	2,961
03-Feb-20	HOLD	3,364
28-May-20	BUY	4,344
03-Nov-20	BUY	5,519
03-Feb-21	BUY	5,712
19-May-21	BUY	6,209
09-Nov-21	BUY	5,437

Source: Bloomberg, Geojit research

Investment Rating Criteria

Ratings	Large caps	Midcaps	Small Caps
Buy	Upside is above 10%	Upside is above 15%	Upside is above 20%
Accumulate	-	Upside is between 10%-15%	Upside is between 10%-20%
Hold	Upside is between 0% - 10%	Upside is between 0%-10%	Upside is between 0%-10%
Reduce/sell	Downside is more than 0%	Downside is more than 0%	Downside is more than 0%
Not rated			

Definition:

Buy: Acquire at Current Market Price (CMP), with the target mentioned in the research note.

Accumulate: Partial buying or to accumulate as CMP dips in the future.

Hold: Hold the stock with the expected target mentioned in the note.

Reduce: Reduce your exposure to the stock due to limited upside.

Sell: Exit from the stock.

Not rated: The analyst has no investment opinion on the stock.

To satisfy regulatory requirements, we attribute 'Accumulate' as Buy and 'Reduce' as Sell.

The recommendations are based on 12 month horizon, unless otherwise specified. The investment ratings are on absolute positive/negative return basis. It is possible that due to volatile price fluctuation in the near to medium term, there could be a temporary mismatch to rating. For reasons of valuations/ return/lack of clarity/event we may revisit rating at appropriate time. Please note that the stock always carries the risk of being upgraded to BUY or downgraded to a HOLD, REDUCE or SELL.

General Disclosures and Disclaimers

CERTIFICATION

I, Rajeev T, author of this Report, hereby certify that all the views expressed in this research report reflect our personal views about any or all of the subject issuer or securities. This report has been prepared by the Research Team of Geojit Financial Services Limited, hereinafter referred to as Geojit.

COMPANY OVERVIEW

Geojit, a publically listed company, is engaged in services of retail broking, depository services, portfolio management and marketing investment products including mutual funds, insurance and properties. GEOJIT is a SEBI registered Research Entity and as such prepares and shares research data and reports periodically with clients, investors, stake holders and general public in compliance with Securities and Exchange Board of India Act, 1992, Securities And Exchange Board Of India (Research Analysts) Regulations, 2014 and/or any other applicable directives, instructions or guidelines issued by the Regulators from time to time.

DISTRIBUTION OF REPORTS: This document is not for public distribution and has been furnished to you solely for your information and must not be reproduced or redistributed to any other person. GEOJIT will not treat the recipients of this report as clients by virtue of their receiving this report.

GENERAL REPRESENTATION: The research reports do not constitute an offer or solicitation for the purchase or sale of any financial instruments, inducements, promise, guarantee, warranty, or as an official confirmation of any transaction or contractual obligations of any kind. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The information contained herein is from publicly available data or other sources believed to be reliable, but we do not represent that it is accurate or complete and it should not be relied on as such. We have also reviewed the research report for any untrue statements of material facts or any false or misleading information. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so.

RISK DISCLOSURE: GEOJIT and/or its Affiliates and its officers, directors and employees including the analyst/authors shall not be in any way be responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Investors may lose his/her entire investment under certain market conditions so before acting on any advice or recommendation in these material, investors should consider



whether it is suitable for their particular circumstances and, if necessary, seek professional advice. This report does not take into account the specific investment objectives, financial situation/circumstances and the particular needs of any specific person who may receive this document. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this report (including the merits and risks involved). The price, volume and income of the investments referred to in this report may fluctuate and investors may realize losses that may exceed their original capital.

FUNDAMENTAL DISCLAIMER: We have prepared this report based on information believed to be reliable. The recommendations herein are based on 12 month horizon, unless otherwise specified. The investment ratings are on absolute positive/negative return basis. It is possible that due to volatile price fluctuation in the near to medium term, there could be a temporary mismatch to rating. For reasons of valuations/return/lack of clarity/event we may revisit rating at appropriate time. The stocks always carry the risk of being upgraded to buy or downgraded to a hold, reduce or sell. The opinions expressed are subject to change but we have no obligation to tell our clients when our opinions or recommendations change. This report is non-inclusive and does not consider all the information that the recipients may consider material to investments. This report is issued by GEOJIT without any liability/undertaking/commitment on the part of itself or any of its entities. We may have issued or may issue on the companies covered herein, reports, recommendations or information which is contrary to those contained in this report. The projections and forecasts described in this report should be evaluated keeping in mind the fact that these are based on estimates and assumptions and will vary from actual results over a period of time. The actual performance of the companies represented in the report may vary from those projected. These are not scientifically proven to guarantee certain intended results and hence, are not published as a warranty and do not carry any evidentiary value whatsoever. These are not predictions and may be subject to change without notice.

CRISIL has provided research support in preparation of this research report and the investment rational contained herein along with financial forecast. The target price and recommendation provided in the report are strictly Geojit's views and are NOT PROVIDED by CRISIL. Further, CRISIL expresses no opinion on valuation and the associated recommendations. CRISIL has no financial liability whatsoever, to the subscribers / users of this report.

JURISDICTION: The securities described herein may not be eligible for sale in all jurisdictions or to all categories of investors. The countries in which the companies mentioned in this report are organized may have restrictions on investments, voting rights or dealings in securities by nationals of other countries. Distributing/taking/sending/dispatching/transmitting this document in certain foreign jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe any such restrictions. Failure to comply with this restriction may constitute a violation of any foreign jurisdiction laws. Foreign currencies denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. Investors in securities such as ADRs, the value of which are influenced by foreign currencies effectively assume currency risk.

REGULATORY DISCLOSURES: GEOJIT's Associates consists of privately held companies such as Geojit Technologies Private Limited (GTPL- Software Solutions provider), Geojit Credits Private Limited (GCPL- NBFC Services provider), Geojit Investment Services Limited (GISL- Corporate Agent for Insurance products), Geojit Financial Management Services Private Limited (GFMSL) & Geojit Financial Distribution Private Limited (GFDPL), (Distributors of Insurance and MF Units). In the context of the SEBI Regulations on Research Analysts (2014), GEOJIT affirms that we are a SEBI registered Research Entity and in the course of our business as a stock market intermediary, we issue research reports /research analysis etc that are prepared by our Research Analysts. We also affirm and undertake that no disciplinary action has been taken against us or our Analysts in connection with our business activities. In compliance with the above mentioned SEBI Regulations, the following additional disclosures are also provided which may be considered by the reader

In compliance with the above mentioned SEBI Regulations, the following additional disclosures are also provided which may be considered b before making an investment decision: 1. Disclosures regarding Ownership:

1. Disclosures regarding C

GEOJIT confirms that:

It/its associates have no financial interest or any other material conflict in relation to the subject company (ies) covered herein.

It/its associates have no actual beneficial ownership of 1% or more in relation to the subject company (ies) covered herein.

Further, the Analyst confirms that:

(i) He, his associates and his relatives have no financial interest in the subject company (ies) covered herein, and they have no other material conflict in the subject company.

(ii)He, His associates and His relatives have no actual/beneficial ownership of 1% or more in the subject company covered

2. Disclosures regarding Compensation:

During the past 12 months, GEOJIT or its Associates:

(a) Have not received any compensation from the subject company; (b) Have not managed or co-managed public offering of securities for the subject company. (c) Have not received any compensation for investment banking or merchant banking or brokerage services from the subject company (d) Have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company. (e) Have not received any compensation or other benefits from the subject company or third party in connection with the research report (f) The subject company is / was not a client during twelve months preceding the date of distribution of the research report.

3. Disclosure by GEOJIT regarding the compensation paid to its Research Analyst:

GEOJIT hereby confirms that no part of the compensation paid to the persons employed by it as Research Analysts is based on any specific brokerage services or transactions pertaining to trading in securities of companies contained in the Research Reports.

4. Disclosure regarding the Research Analyst's connection with the subject company:

It is affirmed that I, Rajeev T, Research Analyst(s) of GEOJIT have not served as an officer, director or employee of the subject company

5. Disclosure regarding Market Making activity:

Neither GEOJIT/its Analysts have engaged in market making activities for the subject company.

Please ensure that you have read the "Risk Disclosure Documents for Capital Market and Derivatives Segments" as prescribed by the Securities and Exchange Board of India before investing.

Geojit Financial Services Ltd. (formerly known as Geojit BNP Paribas Financial Services Ltd.), Registered Office: 34/659-P, Civil Line Road, Padivattom, Kochi-682024, Kerala, India. Phone: +91 484-2901000, Website: www.geojit.com. For investor queries: customercare@geojit.com, For grievances: grievances@geojit.com, For compliance officer: compliance@geojit.com.

Corporate Identity Number: L67120KL1994PLC008403, SEBI Stock Broker Registration No INZ000104737, Research Entity SEBI Reg No: INH200000345, Investment Adviser SEBI Reg No: INA200002817, Portfolio Manager: INP000003203, Depository Participant: IN-DP-325-2017, ARN Regn.Nos:0098, IRDA Corporate Agent (Composite) No.: CA0226

